Otto-Buczkowska Ewa, Jainta Natalia
Medical Specialist Centre in Gliwice, Poland.
Medical University of Silesia in Katowice, Poland.
Int J Endocrinol Metab. 2017 Nov 20;16(1):e13008. doi: 10.5812/ijem.13008. eCollection 2018 Jan.
The basis of treatment in autoimmune diabetes is insulin therapy; however, many clinical cases have proven that this method does not solve all problems. Trials of causal treatment including blocking the autoimmune processes and insulin-producing cells transplants were carried out. Those methods require more research to be concerned as efficient and safe ways of treatment in type 1 diabetes. The use of non-insulin adjunct treatment is a new trend. It has been successfully used in laboratories as well as clinical trials. Metformin is the most widely used drug, together with sodium-glucose co-transporters 2 (SGLT2) inhibitors, amylin analogues, glucagon-like peptide 1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. The results of administration of these medicaments give good outcomes in patients with diabetes mellitus type 1. Most likely, in the near future, they will progressively be used in both adult and adolescent patients with type 1 diabetes. Further multicenter, randomized studies are required to evaluate the efficacy of treatment and long term safety of these drugs.
自身免疫性糖尿病的治疗基础是胰岛素治疗;然而,许多临床病例证明这种方法并不能解决所有问题。开展了包括阻断自身免疫过程和胰岛移植在内的病因治疗试验。作为1型糖尿病高效且安全的治疗方法,这些方法还需要更多研究。使用非胰岛素辅助治疗是一种新趋势。它已在实验室以及临床试验中成功应用。二甲双胍是使用最广泛的药物,还有钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂、胰淀素类似物、胰高血糖素样肽1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂。这些药物的给药结果在1型糖尿病患者中取得了良好疗效。很可能在不久的将来,它们将逐渐用于成年和青少年1型糖尿病患者。需要进一步开展多中心、随机研究来评估这些药物的治疗效果和长期安全性。